Valacyclovir for herpes simplex virus infection: Long-term safety and sustained efficacy after 20 years’ experience with acyclovir

Journal of Infectious Diseases

Volumn 186, Issue , 2002, Pages S40-S46

  Tyring, Stephen K ^a   Baker, David ^b   Snowden, Wendy ^c  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PLACEBO; VALACICLOVIR;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DIARRHEA; DRUG SAFETY; FEVER; GENITAL HERPES; HEADACHE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION; LONG TERM CARE; NAUSEA; NEPHROTOXICITY; PHARYNGITIS; PRIORITY JOURNAL; RASH; RHINITIS; VAGINITIS; VERTIGO;

EID: 0037108422     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/342966     Document Type: Article

References (43)

1. Mertz GJ, Eron L, Kaufman R, et al. Prolonged continuous versus intermittent oral acyclovir treatment in normal adults with frequently recurring genital herpes simplex virus infection. Am J Med 1988;85:14-9.
2. Baker DA, Safrin S, Deeter RG, Walker A, Barton G, and the Aciclovir Study Group. Nine-year effectiveness of continuous suppressive therapy with aciclovir in patients with recurrent genital herpes [abstract P220]. In: Program and abstracts of the Congress of the European Academy of Dermatology and Venereology (Brussels). J Eur Acad Dermatol Venereol 1995;5(Suppl 1):S169.
3. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children-a randomised double blind placebo controlled study. BMJ 1997;314:1800-3.
4. Sullender WM, Arvin AM, Piaz PS, et al. Pharmacokinetics of acyclovir in infants and children. Antimicrob Agents Chemother 1987;31:1722-6.
5. Dunkle LM, Arvin AM, Whitley RJ, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-44.
6. Kimberlin D, Powell D, Gruber W, et al. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996;15:247-54.
7. Reiff-Eldridge R, Heffner CR, Ephross SA, et al. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000;182:159-63.
8. Scott LL, Sanchez PJ, Jackson GL, Zeray F, Wendel GD. Acyclovir suppression to prevent cesarean delivery after first-episode genital herpes. Obstet Gynecol 1996;87:69-73.
9. Stray-Pedersen B. Acyclovir in late pregnancy to prevent neonatal herpes simplex. Lancet 1990;336:756.
10. Brocklehurst P, Kinghorn G, Carney O, et al. A randomised placebo controlled trial of suppressive acyclovir in late pregnancy in women with recurrent genital herpes infection. Br J Obstet Gynaecol 1998;105:275-80.
11. Leen CLS, Mandal BK, Ellis ME, Brettle RP. Acyclovir and pregnancy. BMJ 1987;294:308.
12. Boyd K, Walker E. Use of acyclovir to treat chickenpox in pregnancy. BMJ 1988;296:393-4.
13. De Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother 1983;12(Suppl B):29-37.
14. Weller S, Blum R, Doucette M, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993;54:595-605.
15. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. Genitourin Med 1997;73:110-6.
16. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. J Infect Dis 1998;178:603-10.
17. Patel R, Bodsworth N, Woolley P, et al. Valaciclovir for the suppression of recurrent genital HSV infection: a placebo controlled study of once-daily therapy. Genitourin Med 1997;73:105-9.
18. Conant MA, Schacker T, Murphy RL, et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals-two randomised trials. Int J STD AIDS 2002;13:12-21.
19. Szczech GM. Preclinical development of antiviral drugs. Clin Infect Dis 1996;22:355-60.
20. Baker DA, Blythe JG, Miller JM. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Obstet Gynecol 1999;94:103-6.
21. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997;76:369-80.
22. Ljungman P, de la Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:3050-6.
23. Feinberg JE, Hurwitz S, Cooper D, et al. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. J Infect Dis 1998;177:48-56.
24. Leaf AN, Laubenstein LJ, Raphael B, Hochster H, Baez L, Karpaktin S. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus type 1 (HIV-I) infection. Ann Intern Med 1988;109:194-7.
25. Fish DN, Vidaurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health Syst Pharm 1999;56:1957-60.
26. Eksborg S, Pal N, Kalin M, Palm C, Soderhall S. Pharmacokinetics of acyclovir in immunocompromised children with leukopenia and mucositis after chemotherapy: can intravenous acyclovir be substituted by oral valacyclovir? Med Pediatr Oncol 2002;38:240-6.
27. Simon MW, Fish D, Deeter RG. Pharmacokinetics and safety of valacyclovir in children with EBV illness [abstract 48.006]. Presented at the 8th International Congress on Infectious Diseases, Boston, 1998.
28. Nadal D, Leverger G, Sokal EM, et al. An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children. J Infect Dis 2002;186(Suppl 1):S123-30 (in this issue).
29. Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-70.
30. Kimberlin DF, Weller S, Whitley R, et al. Pharmacokinetics of oral valacyclovir and acyclovir in late pregnancy. Am J Obstet Gynecol 1998;179:846-51.
31. Hill EL, Hunter GA, Ellis MN. In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1991;35:2322-8.
32. Sacks SL, Wanklin RJ, Reece DE, et al. Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med 1989;111:893-9.
33. Safrin S, Kemmer S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;169:193-6.
34. Reyes M, Graber JM, Weatherall N, Hodges-Savola C, Reeves WC. Acyclovir-resistant herpes simplex virus: preliminary results from a national surveillance system. Antiviral Res 1998;37:A44.
35. Christophers J, Clayton J, Craske J, et al. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998;42:868-72.
36. Fife KH, Crumpacker CS, Mertz GJ, Hill EL, Boone GS, Acyclovir Study Group. Recurrence and resistance patterns of herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir. J Infect Dis 1994;169:1338-41.
37. Kost RG, Hill EL, Tigges M, Straus SE. Brief report: recurrent acyclovirresistant genital herpes in an immunocompetent patient. N Engl J Med 1993;329:1777-82.
38. Englund JA, Zimmerman ME, Swierkosz EM, et al. Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 1990;112:416-22.
39. Harden EA, Rybak RJ, Hartline C, et al. Cross susceptibility patterns and neuro-virulence of acyclovir-resistant herpes simplex virus (HSV) isolates collected in a national surveillance study. Antiviral Res 2000;46:A78.
40. Boon RJ, Bacon TH, Robey HL, et al. Antiviral susceptibilities of herpes simplex virus from immunocompetent subjects with recurrent herpes labialis: a UK-based survey. J Antimicrob Chemother 2000;46:324-5.
41. Snowden W, Manohitharajah V, Crooks J. Antiviral sensitivity of herpes simplex virus isolates from patients participating in the valaciclovir genital herpes simplex programme. Antiinfective Drugs Chemother 1998;16(Suppl 1):19.
42. Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993;(Suppl 1):58-66.
43. Weatherall NT, Hodges-Savola CA, Reyes M, et al. Acyclovir-resistant herpes simplex virus: characterization of virus isolates from a nationwide surveillance system. Antiviral Res 1998;37:A44.